CN111035012A - Antioxidant nutrition combination capsule and preparation method thereof - Google Patents
Antioxidant nutrition combination capsule and preparation method thereof Download PDFInfo
- Publication number
- CN111035012A CN111035012A CN201911296257.5A CN201911296257A CN111035012A CN 111035012 A CN111035012 A CN 111035012A CN 201911296257 A CN201911296257 A CN 201911296257A CN 111035012 A CN111035012 A CN 111035012A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- capsule
- antioxidant
- coenzyme
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 72
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 72
- 239000002775 capsule Substances 0.000 title claims abstract description 64
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 50
- 230000035764 nutrition Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 71
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 68
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 68
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 58
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 37
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 37
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 37
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 37
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 33
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 33
- 239000011718 vitamin C Substances 0.000 claims abstract description 33
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 32
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 32
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 32
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 32
- 239000011709 vitamin E Substances 0.000 claims abstract description 32
- 229940046009 vitamin E Drugs 0.000 claims abstract description 32
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 29
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 25
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 25
- 229930182817 methionine Natural products 0.000 claims abstract description 23
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 22
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000036541 health Effects 0.000 claims abstract description 16
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 38
- 229930003779 Vitamin B12 Natural products 0.000 claims description 25
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 25
- 235000019163 vitamin B12 Nutrition 0.000 claims description 25
- 239000011715 vitamin B12 Substances 0.000 claims description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 19
- 235000019152 folic acid Nutrition 0.000 claims description 19
- 239000011724 folic acid Substances 0.000 claims description 19
- 229960000304 folic acid Drugs 0.000 claims description 19
- 108010010803 Gelatin Proteins 0.000 claims description 18
- 239000008273 gelatin Substances 0.000 claims description 18
- 229920000159 gelatin Polymers 0.000 claims description 18
- 235000019322 gelatine Nutrition 0.000 claims description 18
- 235000011852 gelatine desserts Nutrition 0.000 claims description 18
- 239000007901 soft capsule Substances 0.000 claims description 16
- 239000003292 glue Substances 0.000 claims description 15
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 235000013871 bee wax Nutrition 0.000 claims description 8
- 239000012166 beeswax Substances 0.000 claims description 8
- 230000004087 circulation Effects 0.000 claims description 8
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000000227 grinding Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229960003581 pyridoxal Drugs 0.000 claims description 4
- 235000008164 pyridoxal Nutrition 0.000 claims description 4
- 239000011674 pyridoxal Substances 0.000 claims description 4
- 235000008151 pyridoxamine Nutrition 0.000 claims description 4
- 239000011699 pyridoxamine Substances 0.000 claims description 4
- 235000008160 pyridoxine Nutrition 0.000 claims description 4
- 239000011677 pyridoxine Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 239000002390 adhesive tape Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000007723 die pressing method Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 125000002640 tocopherol group Chemical group 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000940 FEMA 2235 Substances 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 229940019897 coenzyme Q10 30 mg Drugs 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000037149 energy metabolism Effects 0.000 abstract description 17
- 230000004060 metabolic process Effects 0.000 abstract description 15
- 239000000126 substance Substances 0.000 abstract description 14
- 230000032683 aging Effects 0.000 abstract description 13
- 230000008558 metabolic pathway by substance Effects 0.000 abstract description 13
- 230000006870 function Effects 0.000 abstract description 12
- 235000015097 nutrients Nutrition 0.000 abstract description 9
- 230000003647 oxidation Effects 0.000 abstract description 9
- 238000007254 oxidation reaction Methods 0.000 abstract description 9
- 230000003712 anti-aging effect Effects 0.000 abstract description 6
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 4
- 235000005289 dietary characteristics Nutrition 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 4
- 229940082632 vitamin b12 and folic acid Drugs 0.000 abstract description 4
- 208000030159 metabolic disease Diseases 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 25
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 23
- 229950006238 nadide Drugs 0.000 description 22
- 150000003254 radicals Chemical class 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 description 12
- 230000003064 anti-oxidating effect Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 9
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 8
- 239000005515 coenzyme Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 6
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- -1 lipid peroxide Chemical class 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 230000004065 mitochondrial dysfunction Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 2
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 2
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-methylenetetrahydrofolic acid Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 2
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 2
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 2
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 2
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 2
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 2
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 2
- 102100029562 Nicotinamide riboside kinase 1 Human genes 0.000 description 2
- 101710134519 Nicotinamide riboside kinase 1 Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000055027 Protein Methyltransferases Human genes 0.000 description 2
- 108700040121 Protein Methyltransferases Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003225 hyperhomocysteinemia Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000027829 mitochondrial depolarization Effects 0.000 description 2
- 235000020956 nicotinamide riboside Nutrition 0.000 description 2
- 239000011618 nicotinamide riboside Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- ZHKQAQKGVKBJPP-YUZLPWPTSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2NC1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZHKQAQKGVKBJPP-YUZLPWPTSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AUFGTPPARQZWDO-YUZLPWPTSA-N 10-formyltetrahydrofolate Chemical compound C1NC=2NC(N)=NC(=O)C=2NC1CN(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YUZLPWPTSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 1
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100034976 Cystathionine beta-synthase Human genes 0.000 description 1
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 101100133505 Mus musculus Nmnat1 gene Proteins 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000037050 permeability transition Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- SQQWBSBBCSFQGC-JLHYYAGUSA-N ubiquinone-2 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O SQQWBSBBCSFQGC-JLHYYAGUSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses an antioxidant nutrition combination capsule for health care, health promotion, life prolonging and a preparation method thereof, belonging to the technical field of health products, wherein β nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C, lipoic acid and other antioxidants are combined, β nicotinamide mononucleotide has the effects of regulating metabolism and prolonging life, mutually enhancing antioxidant and anti-aging effects, is a healthy young state of tissue cells of the whole body and enables life to be longer, is designed aiming at the defects of Chinese dietary characteristics, prevents energy and substance metabolism disorder caused by the deficiency of certain nutrient substances, combines vitamin B6, vitamin B12 and folic acid combination, can promote methionine metabolism by mutual cooperation, realizes the pivot of energy metabolism and substance metabolism of a human body, has the effects of effectively preventing arteriosclerosis, increases coenzyme Q10, has the effects of resisting oxidation, aging and the like, can play a role of protecting heart and important organs of the body, and can maintain the healthy state of functions of the human body.
Description
Technical Field
The invention relates to the technical field of health products, in particular to an antioxidant nutrition combination capsule and a preparation method thereof.
Background
In normal life, the maintenance of life requires complex biochemical reactions in the body to generate energy metabolism and substance metabolism to maintain the normal operation of the functions of various organs of the human body, wherein various substances play an important role in the complex biochemical reactions of the human body, and if the substances are not available, the human body cannot survive, and the substances are considered as important nutrient substances of the human body, including various vitamins, other biochemical substances and the like.
During energy and substance metabolism in the human body, the tricarboxylic acid cycle is the hub of energy metabolism, is performed in mitochondria of cells of the whole body, generates more energy through the tricarboxylic acid cycle, and maintains various physiological and biochemical normal operations of the human body so as to maintain normal functional operation of the human body. However, in the process of generating energy, many kinds of oxidation substances are generated at the same time, and most of the oxidation substances are electrons generated in metabolism, and form oxidation free radicals in tissues, so that the oxidation damage of tissue cells is caused, and the degeneration and the aging of human cell tissues are caused. There is a need for an antioxidant to protect the body from systemic tissue damage caused by oxidative free radicals generated in energy metabolism of the human body at any time, prevent the body from premature aging and aging caused by oxidative damage, and thus prolong the life of the human body.
Most of the antioxidant free radicals on the market are independent antioxidant components, and the components play a certain role in resisting the antioxidant free radicals, so that the health state of an organism is maintained; however, the antioxidant in the market contains single components and has limited antioxidation, cannot better meet the requirement of whole body cell tissue antioxidation, cannot make up for the damage caused by oxidative free radicals generated by various tissue cells of the whole body, and cannot better eliminate the health hidden trouble generated in human body energy metabolism.
With the continuous improvement of the living and health requirements of people, the design of a nutrient substance is more comprehensive, the more perfect antioxidant combination is considered, simultaneously, the nutrient substance which is damaged in the energy and substance metabolism can be supplemented, the aging is delayed, the organism tissue is protected to keep a young state, and the antioxidant composition is the necessary requirement of the antioxidant preparation on the market at present. With the increasing awareness of health and life extension, the demand for such antioxidant combination preparations is increasing.
Disclosure of Invention
The invention provides an antioxidant nutrition combination capsule and a preparation method thereof, which contain more nutrient substances needed in human body energy metabolism, ensure normal energy and substance metabolism of the human body, have obvious antioxidant and anti-aging functions, maintain the health state of human body functions and prolong the service life.
The specific technical scheme provided by the invention is as follows:
on one hand, the antioxidant nutrition combination capsule provided by the invention contains 150-900 mg of β -nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50-300 mg of lipoic acid, 0.4-5 mg of vitamin B6, 10-100 ug of vitamin B12 and 20-200 ug of folic acid.
Optionally, the vitamin B6, the vitamin B12 and the folic acid cooperate with each other to promote methionine circulation.
Optionally, the vitamin E is a fat soluble vitamin, the hydrolysate of the vitamin E is tocopherol, the vitamin C is a polyol, and the vitamin B6 includes pyridoxine, pyridoxal, and pyridoxamine.
Optionally, each of the antioxidant nutritional combination capsules further comprises gelatin, glycerin, water and caramel pigment.
Optionally, each of the antioxidant nutritional combination capsules contains β -nicotinamide mononucleotide (400 mg), coenzyme Q10 (30 mg), vitamin E (300 mg), vitamin C (600 mg), lipoic acid (240 mg), vitamin B6 (4.6 mg), vitamin B12 (85 ug), and folic acid (136 ug).
Optionally, said β -nicotinamide mononucleotide, said coenzyme Q10, said vitamin E, said vitamin C, and said lipoic acid cooperate and act synergistically to form an antioxidant combination.
Optionally, the vitamin E, the vitamin C, and the lipoic acid cooperate with the coenzyme Q10 to achieve a combined antioxidant effect.
In another aspect, the present invention also provides a method for preparing the antioxidant nutritional composition capsule, which includes:
adding distilled water into a gelatin melting tank, soaking gelatin in water to swell, heating to 60 deg.C after gelatin is dissolved, adding glycerol, stirring and mixing to melt gelatin and glycerol into uniform gelatin solution;
keeping the temperature of the glue solution in a glue barrel at 60 ℃ and standing for 5h, then vacuumizing to remove air bubbles and filtering the glue solution, keeping the temperature of the glue solution at 55-60 ℃, and connecting the glue barrel with an automatic rotary capsule machine;
weighing the soybean oil and the beeswax according to the prescription amount, heating to 70 ℃, cooling to room temperature after the beeswax is completely melted, then adding the coenzyme Q10, the vitamin E and the lipoic acid according to the prescription amount, stirring, after the components are uniformly dissolved, sequentially adding the β -nicotinamide mononucleotide, the vitamin C, the vitamin B6, the vitamin B12 and the folic acid according to the prescription amount, grinding for 20min through a colloid mill after primary stirring, and vacuumizing to eliminate bubbles after grinding to obtain the content of the soft capsule;
starting the automatic rotary capsule machine, setting the soft capsule loading amount to be 0.48 g/capsule after each index of the automatic rotary capsule machine is regulated normally, pouring the prepared soft capsule content into a hopper of the soft capsule machine, enabling the liquid medicine to flow into an injector through a discharge pipe, enabling the content to be injected into adhesive tapes on two sides through a spraying body, forming the soft capsule through rolling die pressing, setting for 2 hours under the conditions of 25 ℃ and 25-30% of relative humidity, and then drying for 16 hours at 30 ℃ to obtain the antioxidant nutrition combination capsule.
Optionally, the average particle weight of the antioxidant nutrition combination capsule is 0.472g, the average volume of the content is 0.485mL, and each antioxidant nutrition combination capsule contains 150-900 mg of β -nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50-300 mg of lipoic acid, 0.4-5 mg of vitamin B6, 10-100 ug of vitamin B12 and 20-200 ug of folic acid.
The invention has the following beneficial effects:
the embodiment of the invention provides an antioxidant nutrition combination capsule, which combines β nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C, lipoic acid and other antioxidants, synergistically enhances antioxidant and anti-aging effects, protects tissue cells of the whole body, keeps healthy and young tissue cells of the whole body, enables life to be longer, is designed aiming at the defects of Chinese dietary characteristics, prevents energy and substance metabolism disorder caused by the lack of certain nutrients, combines vitamin B6, vitamin B12 and folic acid combination, can promote methionine metabolism by matching the three components, realizes the pivot of energy metabolism and substance metabolism of a human body, has the effects of effectively preventing arteriosclerosis, enables various human body metabolism to be carried out healthily, increases the effects of antioxidation, anti-aging and the like of coenzyme Q10, can play a role of protecting heart and important organs of the body, and can maintain the health state of functions of the human body.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in further detail below, and it should be apparent that the described embodiments are only a part of the embodiments of the present invention, not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The embodiment of the invention provides an antioxidant nutrition combination capsule which contains 150-900 mg of β -nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50-300 mg of lipoic acid, 0.4-5 mg of vitamin B6, 10-100 ug of vitamin B12 and 20-200 ug of folic acid, wherein the vitamin B6, the vitamin B12 and the folic acid are matched with each other to promote methionine circulation, the vitamin E is a fat-soluble vitamin, a hydrolysate of the vitamin E is tocopherol, the vitamin C is a polyhydroxy compound, and the vitamin B6 comprises pyridoxine, pyridoxal and pyridoxamine.
Preferably, each anti-oxidation nutrition combination capsule contains β -nicotinamide mononucleotide of 400mg, coenzyme Q10 of 30mg, vitamin E of 300mg, vitamin C of 600mg, lipoic acid of 240mg, vitamin B6 of 4.6mg, vitamin B12 of 85ug and folic acid of 136ug, and the anti-oxidation effect of the anti-oxidation nutrition combination capsule in the proportion is the best.
The β -nicotinamide mononucleotide, the coenzyme Q10, the vitamin E, the vitamin C and the lipoic acid in the antioxidant nutrition combination capsule provided by the embodiment of the invention are matched with each other and have synergistic action to form an antioxidant combination, and the vitamin E, the vitamin C and the lipoic acid cooperate with the coenzyme Q10 to realize combined antioxidant effect.
The β Nicotinamide Mononucleotide (NMN) adopted in the antioxidant nutrition combination capsule plays an important role in the generation of human cell energy, participates in the synthesis of intracellular NAD + (also called Nicotinamide adenine dinucleotide, important coenzyme for cell energy conversion), and is a precursor substance of NAD +.
The coenzyme Q10 adopted in the antioxidant nutrition combination capsule provided by the embodiment of the invention not only can provide power for the heart, but also has excellent functions of resisting oxidation and removing free radicals, can prevent lipid peroxidation of blood vessel walls and atherosclerosis, and has no toxic or side effect. Vitamin e (vitamin e) is a fat-soluble vitamin, and the hydrolysate thereof is tocopherol, which is one of the most important antioxidants. Vitamin E can promote reproductive function, protect T lymphocyte, protect erythrocyte, resist free radical oxidation, inhibit platelet aggregation, thereby reducing risk of myocardial infarction and cerebral infarction; also has good curative effect on burn, cold injury, capillary vessel hemorrhage, climacteric syndrome, beauty treatment and the like; can inhibit lipid peroxide reaction in eye lens, dilate peripheral blood vessel, and improve blood circulation; can effectively resist free radicals, inhibit lipid peroxide generation, and remove chloasma; inhibiting tyrosinase activity, thereby reducing melanin production; the esterified vitamin E can also eliminate excessive oxygen free radicals caused by external factors such as ultraviolet rays and air pollution, and has the effects of delaying photoaging, preventing sunburn, inhibiting generation of sunburn erythema and the like.
The vitamin C adopted in the antioxidant nutrition combination capsule provided by the embodiment of the invention is similar to glucose in structure and is a polyhydroxy compound. Vitamin C has strong reducibility and is easily oxidized into dehydrovitamin C, but the reaction is reversible, and ascorbic acid and dehydroascorbic acid have the same physiological functions. Vitamin C is necessary for antibody and collagen formation, tissue repair (including certain redox actions), metabolism of phenylalanine, tyrosine and folic acid, utilization of iron and carbohydrate, synthesis of fat and protein, maintenance of immune function, hydroxylation of 5-hydroxytryptamine, blood vessel integrity maintenance, non-heme iron absorption promotion and the like, and simultaneously the vitamin C also has the effects of oxidation resistance, free radical resistance and tyrosinase inhibition, so that the effects of whitening and spot lightening are achieved. The antioxidation of vitamin C can be understood as a 'protection effect', and the stronger antioxidation of vitamin C can be utilized in modern medical treatment to inhibit the oxidative damage of free radicals to human bodies, thereby preventing the invasion of tumors and cancers.
The lipoic acid adopted in the antioxidant nutrition combination capsule provided by the embodiment of the invention is coenzyme existing in mitochondria, is similar to vitamin, can eliminate free radicals which cause accelerated aging and disease, and has the characteristics of fat solubility and water solubility, and the lipoic acid plays a role in two key oxidative decarboxylation reactions, namely, in a pyruvate dehydrogenase complex and a α -ketoglutarate dehydrogenase complex, the lipoic acid catalyzes the generation and transfer of acyl groups, α -lipoic acid contains a disulfide five-membered ring structure, has high electron density and obvious electrophilicity and the capability of reacting with free radicals, so the lipoic acid has oxidation resistance, has extremely high health care function and medical value (such as the effects of resisting fatty liver and reducing plasma cholesterol), in addition, the sulfhydryl group of the lipoic acid can be easily subjected to redox reaction, the sulfhydryl enzyme can be protected from heavy metal ion poisoning, and the lipoic acid can be easily reduced into dihydrolipoic acid after entering a human body, both can promote the regeneration of vitamin C and vitamin E and play an antioxidant role, and the coenzyme Q10 can increase intracellular glutathione and can also increase metal ions and can play an antioxidant role.
The vitamin B6 adopted in the antioxidant nutrition combination capsule provided by the embodiment of the invention comprises pyridoxine, pyridoxal and pyridoxamine, is a water-soluble vitamin, is easy to damage by light or alkali and cannot resist high temperature. Participating in protein synthesis and catabolism and participating in all amino acid metabolism; participating in protein synthesis and catabolism, participating in all amino acid metabolism, especially methionine metabolism; important substances for maintaining body functions. The adopted vitamin B12 can participate in the synthesis of methionine, thymine and the like, promotes the development and maturation of erythrocytes, has the function of activating amino acid, promotes the biosynthesis of nucleic acid, can promote the anabolism of protein, and ensures that fatty acid, carbohydrate and protein are properly applied by the body; is an indispensable vitamin for the functional perfection of the nervous system, participates in the formation of lipoprotein in nervous tissues and maintains the metabolism and the function of the myelin sheath of the nerve.
β -nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C and lipoic acid cooperate and act synergistically to form an antioxidant combination with a specific health-care effect, wherein β -Nicotinamide Mononucleotide (NMN), which plays an important role in the cellular energy production of the human body, is involved in the synthesis of intracellular NAD + (nicotinamide adenine dinucleotide, an important coenzyme for cellular energy conversion), NAD + is also called coenzyme i, which is known as nicotinamide adenine dinucleotide, also known as nicotinoside diphosphate, there are aspects that are involved in thousands of reactions in each cell, involved in the metabolism of the human body, which is a key coenzyme, but with the increase of age, the NAD + level in the human body is gradually decreasing, at age 40, the NAD + level in the human body is only 25% of the childhood period, after age 80, it decreases to 6.25% of the infant, the decrease of NAD + results in a decrease in mitochondrial activity, mitochondria, cells and even the whole body, and gradually enters the cycle of the childhood, which is a major factor for the supplementation of NAD + and NAD molecules, which is the most responsible for the rapid increase of NAD + production by oral administration, the oral uptake of NAD + is a precursor, which is the most responsible for the rapid rate-limiting factor for the aging of NAD + production of NAD.
NMN is an intermediate in the salvage synthesis pathway of Nicotinamide adenine dinucleotide (NAD +) in mammals. NMN (Nicotinamide mononucleotide) is the product of the Nicotinamide phosphoribosyltransferase (napt) reaction, one of the key precursors of NAD +. In mammals, NMN is produced by Nicotinamide (namide, Nam) catalyzed by Nampt, followed by NMN producing NAD + catalyzed by Nicotinamide mononucleotide adenyl transferase (Nmnat). Extracellular NMN requires dephosphorylation to Nicotinamide Riboside (NR) before entering the interior of hepatocytes, after which NR is phosphorylated by Nicotinamide riboside kinase 1 (NRK 1) to form NMN, which is then combined with ATP to form NAD +. NMN exerts its physiological functions in the human body by being converted to NAD +, such as activating NAD + substrate-dependent enzyme Sirt1 (histone deacetylase, also known as sirtuin), regulating cell survival and death, maintaining redox status, and the like. The regular NMN intake can effectively increase the content of NAD + in vivo, thereby helping human to repair DNA damage, prevent degenerative diseases and delay aging. This is also the core mechanism by which NMN reverses aging and prolongs life.
The tricarboxylic acid cycle (TCA cycle) is a ubiquitous metabolic pathway in aerobic organisms. Prokaryotes are distributed in the cytoplasm, and eukaryotes are distributed in mitochondria. Since several of the major intermediary metabolites in this cycle are organic acids containing three carboxyl groups, such as citric acid, the so-called tricarboxylic acid cycle, also known as the citric acid cycle or the TCA cycle. The tricarboxylic acid cycle is the final metabolic pathway of three major nutrients (carbohydrate, lipid and amino acid) and is also the hub of carbohydrate, lipid and amino acid metabolic connection.
During the tricarboxylic acid cycle, as metabolism proceeds, a large amount of electrons are produced, which are an oxidant, i.e., oxygen radicals, which are normal metabolites of cells, and in general, the production and elimination of free radicals are in a dynamic equilibrium state, and once the equilibrium is broken, the accumulation of free radicals in vivo may cause oxidative stress, leading to peroxidation of DNA, lipids and proteins, causing mitochondrial dysfunction and apoptosis. Oxidative stress and mitochondrial dysfunction are causal, forming a malignant cycle, and causing the degeneration and aging of human metabolic tissues.
Coenzyme Q10 is the only naturally occurring, renewable, lipid-soluble antioxidant in the human body. Coenzyme Q10 exists in 2 forms in the body, including oxidized form and reduced form, 2 forms can be mutually converted in the body, but only reduced coenzyme Q10 can play an anti-oxidation role in the body. The antioxidation of coenzyme Q10 is mainly embodied in scavenging free radicals, synergistic action with other antioxidant substances, resisting apoptosis and stabilizing cell membrane. Coenzyme Q10 can scavenge free radicals in vivo, reduce oxidative stress, and improve mitochondrial dysfunction by converting redox structure.
The mechanism of action of coenzyme Q10 for inhibiting apoptosis may include ① for protecting mitochondrial DNA, coenzyme Q10 for scavenging oxygen free radicals, reducing oxidative stress, preventing mitochondrial DNA mutation caused by peroxidative damage, maintaining mitochondrial respiratory chain integrity, and reducing apoptosis, ② for increasing mitochondrial ATP production efficiency, promoting cell metabolism and growth, and slowing apoptosis, ③ for inhibiting mitochondrial depolarization, coenzyme Q10 for inhibiting mitochondrial permeability transition channel opening, and mitochondrial depolarization, thereby inhibiting cytochrome C release and procaspase-9 (procaspase-9) activation, inhibiting mitochondrial dependent apoptosis pathway activation, and ④ for inhibiting active oxygen (ROS) -related apoptosis pathway in renal proximal tubular cells, coenzyme Q2 for significantly inhibiting nicotine-induced ROS production and apoptosis, and coenzyme Q10 3 for phosphorylating coenzyme Q66 shc, activating antioxidant response element (antioxidant response element 829) and aromatase, and superoxide dismutase (Mn493), thereby promoting aging of heart, and aging, and preventing aging of organism.
The vitamin E, the vitamin C and the lipoic acid in the antioxidant nutritional combination capsule of the embodiment of the invention cooperate with the coenzyme Q10 to realize the combined antioxidant effect. Particularly, the lipoic acid is easy to be reduced into dihydrolipoic acid after entering a human body, and the lipoic acid and the coenzyme Q10 are matched with each other to promote the regeneration of vitamin C and vitamin E and play an antioxidation role. The antioxidant nutrition combination capsule provided by the embodiment of the invention can also increase glutathione and coenzyme Q10 in cells and can chelate certain metal ions. The antioxidant combination can better optimize oxygen free radicals in energy and substance metabolism, resist degeneration and aging of organisms, keep the organisms in a healthy state and prolong the life.
The vitamin B6, the vitamin B12 and the folic acid in the antioxidant nutrition combination capsule have the significance of participating in methionine circulation, the homocysteine (Hcy) is an intermediate product of methionine metabolism, the anabolic pathway and related enzyme systems (methionine synthetase and cystathionine β synthetase) of the Hcy are deficient, and the folic acid, the B12 and the B6 are deficient to cause hyperhomocysteinemia.
A large number of experimental studies show that the methionine circulation is involved in the metabolic mechanism of the organism as follows:
(1) methionine cycling and transmethylation: methionine (methionine) containing S-methyl must be combined with ATP to generate S-adenosylmethionine (SAM, also called active methionine) before transferring methyl, under the action of methyltransferase, methyl can be transferred to methyl group receiver by SAM to make it be methylated to generate methylated product (choline), at the same time, SAM can be converted into S-adenosyl-homocysteine after removing methyl, and can be further removed to generate homocysteine. Homocysteine can receive methyl provided by N5-methyltetrahydrofolic acid to produce methionine (methionine), so that a circulation process called methionine (methionine) circulation is formed. The enzyme catalyzing the conversion of N5-methyltetrahydrofolate to methyl methionine is called methionine synthase (also called methionine methyltransferase, N5-methyltetrahydrofolate methyltransferase), the coenzyme of which is VB12 (vitamin B12), which is involved in the transfer of methyl. A variety of important physiologically active substances containing methyl groups can be produced by various transmethylations, such as: choline can further produce lecithin (promoting myelination) or form acetylcholine (involved in neurotransmitter recovery).
(2) One carbon unit cycle: in addition, in the presence of coenzyme VB12 (vitamin B12), N5-methyltetrahydrofolic acid is demethylated by methionine transferase to form tetrahydrofolic acid, which receives a carbon unit provided by amino acid to form N10-formyltetrahydrofolic acid and then further forms N5, N10-methyltetrahydrofolic acid, which forms N5-methyltetrahydrofolic acid by N5, N10-methylenetetrahydrofolic acid reductase to form another cycle to the "one-carbon unit cycle". Among them, N5, N10-methylenetetrahydrofolate reductase is a key coenzyme for thymidylate synthase, which catalyzes the conversion of deoxyguanosine monophosphate (d-UMP) to deoxythymidine monophosphate (d-TMP) in the reactions necessary for pyrimidine biosynthesis, thereby promoting DNA synthesis and repair.
(3) When VB12 (vitamin B12) is deficient, the methyl of N5-methyltetrahydrofolic acid cannot be transferred, which is not only unfavorable for the generation of methionine, but also influences the transmethylation effect and influences the smooth generation of various physiologically active methylated organisms; meanwhile, the generation of tetrahydrofolic acid is also influenced, so that the free tetrahydrofolic acid in tissues is reduced, the tetrahydrofolic acid cannot be reused for transporting a carbon unit, the synthesis of pyrimidine is influenced, the synthesis of DNA nucleic acid is caused, and the repair is influenced. In addition, when VB12 (vitamin B12) is deficient, homocysteine is influenced to be methylated to generate methionine, so that homocysteine is accumulated, and the hyperhomocysteinemia is considered to have important pathological significance at present and is an independent risk factor of diseases such as atherosclerosis, stroke, dementia and the like.
(4) In certain tissues, such as the liver or kidney, through the process of retro-sulfuration, homocysteine is converted to cystathionine by cystathionine β synthase to further produce cysteine, γ -Glu-cysteine, and finally glutathione.
(5) When folic acid is deficient, one-carbon unit circulation is affected and nucleic acid and protein biosynthesis is affected, leading to disease.
The embodiment of the invention provides an antioxidant nutrition combination capsule, which combines β nicotinamide mononucleotide, coenzyme Q10, vitamin E, vitamin C, lipoic acid and other antioxidants, synergistically enhances antioxidant and anti-aging effects, protects tissue cells of the whole body, keeps healthy and young tissue cells of the whole body, enables life to be longer, is designed aiming at the defects of Chinese dietary characteristics, prevents energy and substance metabolism disorder caused by the lack of certain nutrients, combines vitamin B6, vitamin B12 and folic acid combination, can promote methionine metabolism by matching the three components, realizes the pivot of energy metabolism and substance metabolism of a human body, has the effects of effectively preventing arteriosclerosis, enables various human body metabolism to be carried out healthily, increases the effects of antioxidation, anti-aging and the like of coenzyme Q10, can play a role of protecting heart and important organs of the body, and can maintain the health state of functions of the human body.
In another aspect, the present invention also provides a method for preparing the antioxidant nutritional composition capsule, which includes:
adding distilled water into a gelatin melting tank, soaking gelatin in water to swell, heating to 60 deg.C after gelatin is dissolved, adding glycerol, stirring and mixing to melt gelatin and glycerol into uniform gelatin solution;
keeping the temperature of the glue solution in a glue barrel at 60 ℃ and standing for 5h, then vacuumizing to remove air bubbles and filtering the glue solution, keeping the temperature of the glue solution at 55-60 ℃, and connecting the glue barrel with an automatic rotary capsule machine;
weighing the soybean oil and the beeswax according to the prescription amount, heating to 70 ℃, cooling to room temperature after the beeswax is completely melted, then adding the coenzyme Q10, the vitamin E and the lipoic acid according to the prescription amount, stirring, after the components are uniformly dissolved, sequentially adding the β -nicotinamide mononucleotide, the vitamin C, the vitamin B6, the vitamin B12 and the folic acid according to the prescription amount, grinding for 20min through a colloid mill after primary stirring, and vacuumizing to eliminate bubbles after grinding to obtain the content of the soft capsule;
starting the automatic rotary capsule machine, setting the soft capsule loading amount to be 0.48 g/capsule after each index of the automatic rotary capsule machine is regulated normally, pouring the prepared soft capsule content into a hopper of the soft capsule machine, enabling the liquid medicine to flow into an injector through a discharge pipe, enabling the content to be injected into adhesive tapes on two sides through a spraying body, forming the soft capsule through rolling die pressing, setting for 2 hours under the conditions of 25 ℃ and 25-30% of relative humidity, and then drying for 16 hours at 30 ℃ to obtain the antioxidant nutrition combination capsule.
The antioxidant nutrition combination capsule provided by the embodiment of the invention selects soybean oil as a substrate; the beeswax can play a role in preventing the medicine from settling, so that the medicine is not easy to precipitate when the product is pressed into pills or stored, and the beeswax can be selected as a suspending agent because the formula of the antioxidant nutritional combination capsule contains both oil-soluble nutritional ingredients and water-soluble nutritional ingredients; the capsule wall material of the antioxidant nutrition combination capsule is composed of gelatin and water, a certain amount of glycerin is added to be used as a plasticizer of the capsule shell of the soft capsule, and a certain amount of caramel color is added to the capsule wall material for avoiding light due to the fact that vitamin B6 in the formula has light instability.
The average particle weight of the antioxidant nutrition combination capsule is 0.472g, the average volume of contents is 0.485mL, and each antioxidant nutrition combination capsule contains 150-900 mg of β -nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50-300 mg of lipoic acid, 0.4-5 mg of vitamin B6, 10-100 ug of vitamin B12 and 20-200 ug of folic acid.
The antioxidant nutrition combination capsule of the embodiment of the invention is designed aiming at the defects of Chinese dietary characteristics, prevents energy and substance metabolism disturbance caused by the deficiency of certain nutrients, combines vitamin B6, vitamin B12 and folic acid combination, promotes methionine metabolism, effectively prevents arteriosclerosis and enables various metabolisms of human bodies to be carried out healthily, increases various vitamins, promotes the energy metabolism and substance metabolism of human bodies more comprehensively.
It will be apparent to those skilled in the art that various modifications and variations can be made in the embodiments of the present invention without departing from the spirit or scope of the embodiments of the invention. Thus, if such modifications and variations of the embodiments of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to encompass such modifications and variations.
Claims (9)
1. An antioxidant nutrition combination capsule for health care, rehabilitation and longevity is characterized in that each antioxidant nutrition combination capsule contains 150-900 mg of β -nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50-300 mg of lipoic acid, 0.4-5 mg of vitamin B6, 10-100 ug of vitamin B12 and 20-200 ug of folic acid.
2. The antioxidant nutritional combination capsule of claim 1, wherein the vitamin B6, vitamin B12, and folic acid cooperate to promote methionine circulation.
3. The antioxidant nutritional combination capsule of claim 1 or 2, wherein the vitamin E is a fat soluble vitamin, the hydrolysis product of vitamin E is tocopherol, the vitamin C is a polyol, and the vitamin B6 comprises pyridoxine, pyridoxal and pyridoxamine.
4. The antioxidant nutritional combination capsule of claim 1 further comprising gelatin, glycerin, water, and caramel color per capsule.
5. The antioxidant nutritional combination capsule of any one of claims 1-4, wherein each of the antioxidant nutritional combination capsules comprises β -nicotinamide mononucleotide 400mg, coenzyme Q10 30mg, vitamin E300 mg, vitamin C600 mg, lipoic acid 240mg, vitamin B6 4.6mg, vitamin B12 85ug, and folic acid 136 ug.
6. The antioxidant nutritional combination capsule of claim 5, wherein the β -nicotinamide mononucleotide, the coenzyme Q10, the vitamin E, the vitamin C, and the lipoic acid cooperate and cooperate to form an antioxidant combination.
7. The antioxidant nutritional combination capsule of claim 6, wherein the vitamin E, the vitamin C, and the lipoic acid cooperate with the coenzyme Q10 to achieve a combined antioxidant effect.
8. A method for preparing the antioxidant nutrition combination capsule for health care, help longevity according to any one of claims 1 to 7, which comprises:
adding distilled water into a gelatin melting tank, soaking gelatin in water to swell, heating to 60 deg.C after gelatin is dissolved, adding glycerol, stirring and mixing to melt gelatin and glycerol into uniform gelatin solution;
keeping the temperature of the glue solution in a glue barrel at 60 ℃ and standing for 5h, then vacuumizing to remove air bubbles and filtering the glue solution, keeping the temperature of the glue solution at 55-60 ℃, and connecting the glue barrel with an automatic rotary capsule machine;
weighing the soybean oil and the beeswax according to the prescription amount, heating to 70 ℃, cooling to room temperature after the beeswax is completely melted, then adding the coenzyme Q10, the vitamin E and the lipoic acid according to the prescription amount, stirring, after the components are uniformly dissolved, sequentially adding the β -nicotinamide mononucleotide, the vitamin C, the vitamin B6, the vitamin B12 and the folic acid according to the prescription amount, grinding for 20min through a colloid mill after primary stirring, and vacuumizing to eliminate bubbles after grinding to obtain the content of the soft capsule;
starting the automatic capsule rotating machine, setting the soft capsule loading amount to be 0.48 g/capsule after each index of the automatic capsule rotating machine is regulated to be normal, pouring the prepared soft capsule content into a hopper of the soft capsule machine, enabling the liquid medicine to flow into an injector through a discharge pipe, enabling the content to be injected into adhesive tapes on two sides through a spraying body, forming the soft capsule through rolling die pressing, setting for 2 hours under the conditions of 25 ℃ and 25-30% of relative humidity, and then drying for 16 hours at 30 ℃ to obtain the antioxidant nutrition combination capsule for health care, help and longevity.
9. The method for preparing the antioxidant nutrition combination capsule for health care, life support and longevity according to claim 8, wherein the average particle weight of the antioxidant nutrition combination capsule is 0.472g, the average volume of the content is 0.485mL, each antioxidant nutrition combination capsule contains 150-900 mg of β -nicotinamide mononucleotide, 10-50 mg of coenzyme Q10, 50-500 mg of vitamin E, 100-1000 mg of vitamin C, 50-300 mg of lipoic acid, 0.4-5 mg of vitamin B6, 10-100 ug of vitamin B12 and 20-200 ug of folic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911296257.5A CN111035012A (en) | 2019-12-16 | 2019-12-16 | Antioxidant nutrition combination capsule and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911296257.5A CN111035012A (en) | 2019-12-16 | 2019-12-16 | Antioxidant nutrition combination capsule and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111035012A true CN111035012A (en) | 2020-04-21 |
Family
ID=70236799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911296257.5A Pending CN111035012A (en) | 2019-12-16 | 2019-12-16 | Antioxidant nutrition combination capsule and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111035012A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111529693A (en) * | 2020-05-06 | 2020-08-14 | 林�吉 | Health-care medicine containing polypeptide gel for activating body cell function and its preparing process |
CN111939154A (en) * | 2020-08-24 | 2020-11-17 | 周琛 | Anti-aging composition, application thereof, and health food and medicine containing anti-aging composition |
CN111972664A (en) * | 2020-08-10 | 2020-11-24 | 陈方红 | Health-care capsule |
CN112022832A (en) * | 2020-09-24 | 2020-12-04 | 玉溪健坤生物药业有限公司 | High-quality formula raw material of NAD respiratory chain and method for preparing soft capsule contents |
CN112451494A (en) * | 2020-11-11 | 2021-03-09 | 武汉林宝莱生物科技有限公司 | Pyrroloquinoline quinone formula and NMN preparation formula preparation method |
CN112641091A (en) * | 2020-11-25 | 2021-04-13 | 北京斯利安药业有限公司 | Composite antioxidant containing folic acid |
CN113208117A (en) * | 2021-06-03 | 2021-08-06 | 泰州职业技术学院 | Composition containing NMN and taurine and application thereof |
CN113786352A (en) * | 2021-10-28 | 2021-12-14 | 吉林百奥生物科技有限公司 | Anti-aging essence containing nicotinamide mononucleotide and preparation method thereof |
CN114272356A (en) * | 2022-01-12 | 2022-04-05 | 孟庆雄 | Formula and preparation method of anti-aging pharmaceutical composition |
WO2022077276A1 (en) * | 2020-10-14 | 2022-04-21 | 音芙医药科技(上海)有限公司 | Application of combination of nicotinamide mononucleotide and lactobacillus fermentum in preparation of formulation for relieving skin photoaging |
WO2023004690A1 (en) * | 2021-07-29 | 2023-02-02 | 山东赛珥医药科技有限公司 | Antioxidant nutrition composition capsule |
CN116637106A (en) * | 2022-02-15 | 2023-08-25 | 四川大学 | Health care product or medicine with antioxidation effect |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1524447A (en) * | 2003-09-16 | 2004-09-01 | 曾繁玉 | Antioxidant compositions |
CN103599137A (en) * | 2013-08-16 | 2014-02-26 | 李桂霞 | Health food containing plurality of trace nutrient elements |
CN104705652A (en) * | 2015-03-30 | 2015-06-17 | 哈尔滨工业大学 | Soft capsule with anti-oxidation function and preparation method of soft capsule |
CN105876435A (en) * | 2014-10-22 | 2016-08-24 | 会同县贤胜油业有限责任公司 | Anti-oxidizing composition soft capsule and preparation method thereof |
CN106072659A (en) * | 2016-06-29 | 2016-11-09 | 中国人民解放军第三军医大学第附属医院 | Multielement organism antioxidants compositions and application thereof |
CN108391816A (en) * | 2017-02-08 | 2018-08-14 | 阙燕娣 | A kind of production method of antioxidant healthcare capsule |
CN110237105A (en) * | 2019-07-05 | 2019-09-17 | 湖北真福医药有限公司 | A kind of potent oxidation resisting soft capsule and preparation method thereof |
-
2019
- 2019-12-16 CN CN201911296257.5A patent/CN111035012A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1524447A (en) * | 2003-09-16 | 2004-09-01 | 曾繁玉 | Antioxidant compositions |
CN103599137A (en) * | 2013-08-16 | 2014-02-26 | 李桂霞 | Health food containing plurality of trace nutrient elements |
CN105876435A (en) * | 2014-10-22 | 2016-08-24 | 会同县贤胜油业有限责任公司 | Anti-oxidizing composition soft capsule and preparation method thereof |
CN104705652A (en) * | 2015-03-30 | 2015-06-17 | 哈尔滨工业大学 | Soft capsule with anti-oxidation function and preparation method of soft capsule |
CN106072659A (en) * | 2016-06-29 | 2016-11-09 | 中国人民解放军第三军医大学第附属医院 | Multielement organism antioxidants compositions and application thereof |
CN108391816A (en) * | 2017-02-08 | 2018-08-14 | 阙燕娣 | A kind of production method of antioxidant healthcare capsule |
CN110237105A (en) * | 2019-07-05 | 2019-09-17 | 湖北真福医药有限公司 | A kind of potent oxidation resisting soft capsule and preparation method thereof |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111529693A (en) * | 2020-05-06 | 2020-08-14 | 林�吉 | Health-care medicine containing polypeptide gel for activating body cell function and its preparing process |
CN111972664A (en) * | 2020-08-10 | 2020-11-24 | 陈方红 | Health-care capsule |
CN111939154A (en) * | 2020-08-24 | 2020-11-17 | 周琛 | Anti-aging composition, application thereof, and health food and medicine containing anti-aging composition |
CN112022832A (en) * | 2020-09-24 | 2020-12-04 | 玉溪健坤生物药业有限公司 | High-quality formula raw material of NAD respiratory chain and method for preparing soft capsule contents |
WO2022077276A1 (en) * | 2020-10-14 | 2022-04-21 | 音芙医药科技(上海)有限公司 | Application of combination of nicotinamide mononucleotide and lactobacillus fermentum in preparation of formulation for relieving skin photoaging |
CN112451494A (en) * | 2020-11-11 | 2021-03-09 | 武汉林宝莱生物科技有限公司 | Pyrroloquinoline quinone formula and NMN preparation formula preparation method |
CN112641091A (en) * | 2020-11-25 | 2021-04-13 | 北京斯利安药业有限公司 | Composite antioxidant containing folic acid |
CN113208117A (en) * | 2021-06-03 | 2021-08-06 | 泰州职业技术学院 | Composition containing NMN and taurine and application thereof |
WO2023004690A1 (en) * | 2021-07-29 | 2023-02-02 | 山东赛珥医药科技有限公司 | Antioxidant nutrition composition capsule |
CN113786352A (en) * | 2021-10-28 | 2021-12-14 | 吉林百奥生物科技有限公司 | Anti-aging essence containing nicotinamide mononucleotide and preparation method thereof |
CN114272356A (en) * | 2022-01-12 | 2022-04-05 | 孟庆雄 | Formula and preparation method of anti-aging pharmaceutical composition |
WO2023133984A1 (en) * | 2022-01-12 | 2023-07-20 | Meng Qingxiong | An anti-aging pharmaceutical composition and preparation method thereof |
CN116637106A (en) * | 2022-02-15 | 2023-08-25 | 四川大学 | Health care product or medicine with antioxidation effect |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111035012A (en) | Antioxidant nutrition combination capsule and preparation method thereof | |
US9623042B2 (en) | Combination preparation for improving sperm quality | |
US6451341B1 (en) | Time release formulation of vitamins, minerals and other beneficial supplements | |
KR20070083734A (en) | Method and composition for supplementation of nutritional deficiencies in renal patients | |
US20100124587A1 (en) | Creatine-containing vitamin and mineral composition | |
US8642030B2 (en) | Compositions containing coenzyme Q-10 and dihydrolipoic acid | |
Novotny et al. | Alpha-lipoic acid-the potential for use in cancer therapy minireview | |
US20020025310A1 (en) | Compositions and methods for promoting healthy joints | |
Gonzalez et al. | Mitochondrial correction: a new therapeutic paradigm for cancer and degenerative diseases | |
US20240082197A1 (en) | Delivery methods for omega-3's and compositions for vitamins and minerals used to enhance visual acuity and mental development in the human body | |
Livesey | Methionine degradation:‘anabolic and catabolic’ | |
EP4122536A1 (en) | Coenzyme q production promoter and coenzyme q production promoting method | |
JP5931324B2 (en) | Composition for reducing oxidative stress and / or side effects caused during cancer chemotherapy or improving nutritional status during cancer chemotherapy | |
WO2023004690A1 (en) | Antioxidant nutrition composition capsule | |
CN113615833A (en) | Mitochondrial nutrient composition for improving cardiovascular disease and application thereof | |
CN113841887A (en) | Auxiliary enzyme nutrient-deficient compound tablet and preparation method thereof | |
CA2291959A1 (en) | A nutriceutical composition of l-carnitine, ubiquinone, n-3 polyunsaturated fatty acids and vitamins specifically formulated at pharmacological doses for the amelioration of the risk factors and symptoms of atherosclerosis-related illnesses | |
CA2366766A1 (en) | Glycoprotein matrix compositions and methods related thereto | |
JPWO2006104153A1 (en) | Composition for enhancing antioxidant activity in blood | |
WO2017218004A1 (en) | Medical food for patients with chronic liver disease | |
Lykkesfeldt | Vitamin C pharmacokinetics | |
Gao-Balch | Reconsidered B-vitamins play a vital role in maintaining good health and well-being | |
Alturfan | Water-soluble vitamins | |
Finkelstein et al. | Effect of nicotinamide on methionine metabolism in rat liver | |
Mukherjee et al. | The role of B vitamins in protecting mitochondrial function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |